Novartis announced  that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis.1 The

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In